Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Clinical MRD Oncology Tests Processed by Quarter
Clinical MRD Oncology Tests Processed — Quarterly (thousand tests)
Natera Clinical MRD Oncology Tests Processed: 283.00 k_tests in Q2 2026, up 56.4% from a year earlier. That is the highest of the 13 quarters on record here.
Where the Q2 2026 figure comes from
“5 Not for reproduction or further distribution. Clinical MRD volumes: record volume of ~283K units 489K 1Q24 181K 202K 225K 249K Record sequential growth of ~34K units”
Source: Form 8-K Ex 99.2 Q2 2026 Presentation (2026-08-06) ↗
Quarterly clinical minimal residual disease (MRD) oncology tests (Signatera clinical testing, excluding biopharma research and clinical trial units), reported in thousands.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Natera Clinical MRD Oncology Tests Processed, quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-clinical-mrd-oncology-tests
See every metric in the Natera KPI table. Data updated Nov 2, 2026.